Absci Corporation
ABSIHealthcareNASDAQBiotechnology · Last scanned Jun 1, 2026
Scan Results
Daily timeframeAbsci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. The company carries a $1.05B market cap, placing it firmly in the small-cap category. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.
Market Cap
$1.05B
Beta
2.38
P/E (TTM)
—
P/E (Fwd)
-10.63
EPS (TTM)
$-0.82
EPS (Fwd)
$-0.64
ROE
-63.9%
ROA
-37.3%
Cash
$125.7M
Total Debt
$4.4M
Free CF
-$41.5M
52W Change
147.3%
Annual Financials
Cash vs Debt
With $125.7M in cash and $4.4M in debt, ABSI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$41.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -63.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.7M (2022) to $2.8M (2025), a 51% decline worth watching.
With a beta above 1.5, ABSI tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, ABSI has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Absci Corporation and its sector.